Curtis Jeffrey R, Westfall Andrew O, Allison Jeroan, Becker Angela, Melton Mary Elkins, Freeman Allison, Kiefe Catarina I, MacArthur Marilyn, Ockershausen Theresa, Stewart Emily, Weissman Norm, Saag Kenneth G
Center for Education and Research on Therapeutics of Musculoskeletal Diseases, University of Alabama at Birmingham, AL 35294, USA
Arch Intern Med. 2007 Mar 26;167(6):591-6. doi: 10.1001/archinte.167.6.591.
In light of widespread undertreatment for glucocorticoid-induced osteoporosis (GIOP), we designed a group randomized controlled trial to increase bone mineral density (BMD) testing and osteoporosis medication prescribing among patients receiving long-term glucocorticoid therapy.
Using administrative databases of a large US health plan, we identified physicians who prescribed long-term glucocorticoid therapy to at least 3 patients. One hundred fifty-three participating physicians were randomized to receive a 3-module Web-based GIOP intervention or control course. Intervention modules focused on GIOP management and incorporated case-based continuing medical education and personalized audit and feedback of GIOP management compared with that of the top 10% of study physicians. In the year following the intervention, we compared rates of BMD testing and osteoporosis medication prescribing between intervention and control physicians.
Following the intervention, intent-to-treat analyses showed that 78 intervention physicians (472 patients) vs 75 control physicians (477 patients) had similar rates of BMD testing (19% vs 21%, P = .48; rate difference, -2%; 95% confidence interval [CI], -8% to 4%) and osteoporosis medication prescribing (32% vs 29%, P = .34; rate difference, 3%; 95% CI, -3% to 9%). Among 45 physicians completing all modules (343 patients), intervention physicians had numerically but not significantly higher rates of BMD testing (26% vs 16%, P =.04; rate difference, 10%; 95% CI, 1%-20%) and bisphosphonate prescribing (24% vs 17%, P =.09; rate difference, 7%; 95% CI, -1% to 16%) or met a combined end point of BMD testing or osteoporosis medication prescribing (54% vs 44%, P =.07; rate difference, 10%; 95% CI, -1% to 21%) compared with control physicians.
In the main analysis, a Web-based intervention incorporating performance audit and feedback and case-based continuing medical education had no significant effect on the quality of osteoporosis care. However, dose-response trends showed that physicians with greater exposure to the intervention had higher rates of GIOP management. New cost-effective modalities are needed to improve the quality of osteoporosis care.
鉴于糖皮质激素诱导的骨质疏松症(GIOP)治疗不足的情况普遍存在,我们设计了一项群组随机对照试验,以增加接受长期糖皮质激素治疗患者的骨密度(BMD)检测及骨质疏松症药物处方。
利用美国一个大型健康计划的管理数据库,我们确定了至少为3名患者开具长期糖皮质激素治疗处方的医生。153名参与的医生被随机分为接受一个基于网络的3模块GIOP干预课程或对照课程。干预模块聚焦于GIOP管理,并纳入了基于病例的继续医学教育以及与研究医生中排名前10%的医生相比的GIOP管理个性化审核与反馈。在干预后的一年里,我们比较了干预组和对照组医生的BMD检测率及骨质疏松症药物处方率。
干预后,意向性分析显示,78名干预组医生(472名患者)与75名对照组医生(477名患者)的BMD检测率相似(19%对21%,P = 0.48;率差为 -2%;95%置信区间[CI]为 -8%至4%),骨质疏松症药物处方率也相似(32%对29%,P = 0.34;率差为3%;95% CI为 -3%至9%)。在完成所有模块的45名医生(343名患者)中,干预组医生的BMD检测率在数值上较高但无显著差异(26%对16%,P = 0.04;率差为10%;95% CI为1%至20%),双膦酸盐处方率也较高(24%对17%,P = 0.09;率差为7%;95% CI为 -1%至16%),或者达到BMD检测或骨质疏松症药物处方的综合终点的比例较高(54%对44%,P = 0.07;率差为10%;95% CI为 -1%至21%),与对照组医生相比。
在主要分析中,一个纳入绩效审核与反馈以及基于病例的继续医学教育的网络干预对骨质疏松症护理质量没有显著影响。然而,剂量反应趋势表明,更多接触干预的医生有更高的GIOP管理率。需要新的具有成本效益的方式来提高骨质疏松症护理质量。